Business Description
Founded in 2013 and headquartered in Luxembourg, Alvotech is a global biopharmaceutical company focused entirely on developing and producing biosimilar medicines. Its portfolio targets a broad range of serious conditions, including inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis, as well as eye disorders, bone-related conditions in cancer patients, allergic asthma, and certain cancers. The company has built a pipeline of more than eight biosimilar products, each designed to replicate the safety and effectiveness of well-established treatments at potentially lower costs. Alvotech serves patients across multiple continents, working with partners to bring its medicines to markets around the world.
